Clinical Trial

Metabolic Features Effects on FAST Score in MASLD Patients

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 10, 2025 (before its estimated March 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational cross-sectional study is to evaluate the effect of metabolic features on Fibroscan-AST (FAST) score stratification in metabolic dysfunction-associated steatotic liver disease (MASLD) patients in Egypt. Researchers will identify the metabolic risk factors in patients with MASLD. evaluate the effect of metabolic features on stratifying MASLD patients by predicting higher FAST score. Participants will be subjected to history taking, clinical examination, laboratory investigations, abdominal ultrasonography, and transient elastography (Fibroscan) to measure liver stiffness (LSM) and controlled attenuation parameter (CAP). The Non-alcoholic fatty liver disease (NAFLD) fibrosis score and FAST score will be calculated.
Trial Details
NCT Number NCT06867419
Lead Sponsor Tanta University
Conditions Metabolic Dysfunction-Associated Steatotic Liver Disease
Enrollment 385 participants
Start Date 2024-09-01
Primary Completion 2025-03-30 (estimated)
Study Completion 2025-03-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-10